Get started
Author

S. Vázquez Estévez

Observed names: S V Estévez, S Vazquez Estevez, S. Vazquez Estevez, S. Vázquez Estevez
ORCID: 0009-0001-1456-0178
Observed ORCID: 0009-0001-1456-0178
OpenAlex ID: A5111949211
OA12.05 APOLO: Phase II Trial of Induction Chemo-Immunotherapy Plus Chemoradiotherapy and Maintenance Immunotherapy in Stage III NSCLC
2024 · M. Provencio, B. Campos, et al. · Journal of Thoracic Oncology · 25
761P Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB trial
2020 · J.F. Rodriguez-Moreno, G. de Velasco, et al. · Annals of Oncology · 17
PDF
Gemcitabine, cisplatin and vinorelbine as induction chemotherapy followed by radical therapy in stage III non-small-cell lung cancer: a multicentre study of galician-lung-cancer-group
2003 · L León, Juan F Cueva-Banuelos, et al. · Lung Cancer · 12
PROSTRATEGY: A Spanish Genitourinary Oncology Group (SOGUG) multi-arm multistage (MAMS) phase III trial of immunotherapy strategies in high-volume metastatic hormone-sensitive prostate cancer
2019 · J A Arranz Arija, B.P. Valderrama, et al. · Annals of Oncology · 3
PDF
Implications of single nucleotide polymorphisms (SNPs) in androgen related-genes in outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (Abi) and enzalutamide (Enza)
2019 · I.M. Aragon, Y. Cendón, et al. · Annals of Oncology · 3
SPAZO2 (SOGUG): Comparative effectiveness of pazopanib in metastatic renal carcinoma (mRC): Ineligible (I) vs eligible (E) patients for clinical trials
2017 · J. Arranz Arija, B. Pérez Valderrama, et al. · Annals of Oncology · 2
PDF
Gemcitabine/docetaxel (GD) vs gemcitabine/cisplatin (GC) in stage IIIB/IV advanced non-small cell lung cancer (NSCLC)
2006 · J. Casal Rubio, S. Vázquez Estevez, et al. · Journal of Clinical Oncology · 2
1783P PROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Efficacy results from the pilot phase
2023 · J.A. Arranz Arija, J.M. Piulats Rodriguez, et al. · Annals of Oncology · 1
PDF
639P 223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide
2020 · J. Carles, T. Alonso, et al. · Annals of Oncology · 1
PDF
A phase II study of biweekly docetaxel and vinorelbine for hormone-refractory prostate cancer (HRPC)
2006 · S. Vázquez Estévez, J. Mel Lorenzo, et al. · Journal of Clinical Oncology · 1
Real world experience with enfortumab- vedotin- pembrolizumab as first line treatment for metastasic bladder cancer in geriatric population
2026 · I. González Crujeiras, B.I. Távara Silva, et al. · Journal of Geriatric Oncology
Neoadjuvant nivolumab plus gemcitabine–cisplatin followed by postsurgical adjuvant nivolumab versus neoadjuvant gemcitabine–cisplatin in patients with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial
2026 · G. Sonpavde, M.S. van der Heijden, et al. · Annals of Oncology
PDF
122P Analysis of the impact of age and brain metastases in first-line treatment of advanced non-small cell lung cancer (NSCLC) based on real-world data: REVEAL study
2026 · J. Coves Sarto, F.D.A. Aparisi Aparisi, et al. · ESMO Open
59P Analysis from the Spanish registry of thoracic tumors: Characterisation of patients with BRAF-mutated non-small cell lung cancer
2026 · D. Rodriguez-Abreu, E. Carcereny, et al. · ESMO Open
PDF
183eP Real-world treatment and response patterns in patients with metastatic non-small cell lung cancer in Spain: REVEAL study
2026 · C. Aguado de la Rosa, F.D.A. Aparisi Aparisi, et al. · ESMO Open
Real-world experience with enfortumab vedotin as palliative therapy in advanced urothelial carcinoma after progression to platinum-based chemotherapy and immune checkpoint inhibitors
2025 · J.A. Folgueira Vigo, I. González Crujeiras, et al. · European Urology Open Science
374P: Prognostic relevance of post-cycle 1 pembrolizumab levels in real-world NSCLC patients receiving first line IO or ChIO
2025 · C. Martinez, M. Molina Alejandre, et al. · Journal of Thoracic Oncology
1577P Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study
2024 · M. Garcia De Herreros, M.B. Bernabeu Aracil, et al. · Annals of Oncology
PDF
1376P Early detection of disease progression in NSCLC patients undergoing immunotherapy through ctDNA analysis
2024 · V. Calvo de Juan, L. Robado de Lope, et al. · Annals of Oncology
PDF
1793P PPROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Safety and toxicity profiles from the pilot phase
2023 · J.A. Arranz Arija, S. Vazquez Estevez, et al. · Annals of Oncology
PDF
EP08.02-070 High Incidence of Peridiagnosis Thromboembolic Events In Patients with BRAF Mutant Lung Cancer
2022 · I. Aparicio Salcedo, P. Iranzo Gómez, et al. · Journal of Thoracic Oncology
55P MOREL: Multicenter observational study on treatment and PD-L1 testing in patients (pts) with newly diagnosed stage IV NSCLC in Spain
2020 · B. Rubio-Viqueira, M. Majem Tarruella, et al. · Annals of Oncology
759P Towards personalized medicine in MIBC: Immunohistochemistry-based taxonomical classification and outcome in patients treated with adjuvant chemotherapy
2020 · D. Castellano Gauna, E. Grande, et al. · Annals of Oncology
Factors Influencing Long Term Survival in Metastatic Castration Resistant Prostate Cancer Patients: a Spanish Multicentre Experience
2020 · S Vazquez Estevez · Cancer therapy & Oncology International Journal
PDF
SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz)
2019 · B.P. Valderrama, S. Perez Ramirez, et al. · Annals of Oncology
PDF
Works count: 33
Citation count: 67
H-index: 3
I10-index: 3
Year
Topic
Type